A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II
CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine
Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell
lymphoma